Literature DB >> 22417068

Pandemic (H1N1) 2009 influenza in Canadian pediatric cancer and hematopoietic stem cell transplant patients.

Dat Tran1, Michelle Science, David Dix, Carol Portwine, Shayna Zelcer, Donna L Johnston, Rochelle Yanofsky, Adam Gassas, Marie-Chantal Ethier, Lillian Sung.   

Abstract

BACKGROUND: The impact of pandemic H1N1 influenza (pH1N1) virus in pediatric cancer is uncertain. The objectives of this study were to characterize the clinical course of pH1N1 and identify factors associated with severe outcomes.
METHODS: We conducted a Canadian multicenter retrospective review of children with cancer and stem cell transplant (SCT) recipients who were diagnosed with laboratory-confirmed pH1N1 infection between May 1, 2009 and January 31, 2010.
RESULTS: We identified 100 (19 in wave 1 and 81 in wave 2) cases of pH1N1 infection. Median age was 8.7 years. 71% had a hematologic malignancy, and 20% received SCT. Median duration of fever and illness was 2 and 12.5 days, respectively. 51 (51.5%) were hospitalized for a median of 5 days, with no deaths and only 1 requiring admission to the intensive care unit. Radiologically confirmed pneumonia was diagnosed in 10 (10%). Interruption of chemotherapy or conditioning occurred in 43 patients. In multivariable analyses, age <5 years (relative to ≥ 10 years) and neutropenia were associated with hospitalization while neutropenia was associated with pneumonia. Despite oseltamivir use in 89%, viral shedding was prolonged (median, 46 days) and often persisted after symptom resolution. However, an extended treatment course (>5 days) correlated with shortened duration of viral shedding (P=0.041).
CONCLUSIONS: pH1N1 infection in pediatric cancer and SCT patients infrequently caused complications but commonly interrupted cancer treatment. Persistent shedding of virus after illness resolution was common. Further research is needed to verify this finding as it could have implications for treatment guidelines and infection control practices.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22417068      PMCID: PMC4941707          DOI: 10.1111/j.1750-2659.2012.00352.x

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


  41 in total

1.  Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community.

Authors:  P McMinn; A Carrello; C Cole; D Baker; A Hampson
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  Summary recommendations by the Advisory Committee on Immunization Practices (ACIP) for the use of H1N1 influenza vaccine for the 2009-2010 vaccination season.

Authors:  Sheila M Litchfield
Journal:  AAOHN J       Date:  2009-09

3.  Incidence of hospital admissions and severe outcomes during the first and second waves of pandemic (H1N1) 2009.

Authors:  Melissa Helferty; Julie Vachon; Jill Tarasuk; Rachel Rodin; John Spika; Louise Pelletier
Journal:  CMAJ       Date:  2010-11-08       Impact factor: 8.262

4.  A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1).

Authors:  Janice K Louie; Meileen Acosta; Michael C Samuel; Robert Schechter; Duc J Vugia; Kathleen Harriman; Bela T Matyas
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

5.  Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial.

Authors:  Santtu Heinonen; Heli Silvennoinen; Pasi Lehtinen; Raija Vainionpää; Tero Vahlberg; Thedi Ziegler; Niina Ikonen; Tuomo Puhakka; Terho Heikkinen
Journal:  Clin Infect Dis       Date:  2010-10-15       Impact factor: 9.079

6.  Influenza in children with cancer.

Authors:  A Kempe; C B Hall; N E MacDonald; H R Foye; K A Woodin; H J Cohen; E D Lewis; M Gullace; C L Gala; C S Dulberg; E Katsanis
Journal:  J Pediatr       Date:  1989-07       Impact factor: 4.406

7.  Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.

Authors:  W Garrett Nichols; Katherine A Guthrie; Lawrence Corey; Michael Boeckh
Journal:  Clin Infect Dis       Date:  2004-10-11       Impact factor: 9.079

8.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.

Authors:  Ana Clara Monsalvo; Juan P Batalle; M Florencia Lopez; Jens C Krause; Jennifer Klemenc; Johanna Zea Hernandez; Bernardo Maskin; Jimena Bugna; Carlos Rubinstein; Leandro Aguilar; Liliana Dalurzo; Romina Libster; Vilma Savy; Elsa Baumeister; Liliana Aguilar; Graciela Cabral; Julia Font; Liliana Solari; Kevin P Weller; Joyce Johnson; Marcela Echavarria; Kathryn M Edwards; James D Chappell; James E Crowe; John V Williams; Guillermina A Melendi; Fernando P Polack
Journal:  Nat Med       Date:  2010-12-05       Impact factor: 53.440

9.  Clinical aspects and cytokine response in severe H1N1 influenza A virus infection.

Authors:  Natalia Hagau; Adriana Slavcovici; Daniel N Gonganau; Simona Oltean; Dan S Dirzu; Erika S Brezoszki; Mihaela Maxim; Constantin Ciuce; Monica Mlesnite; Rodica L Gavrus; Carmen Laslo; Radu Hagau; Magda Petrescu; Daniela M Studnicska
Journal:  Crit Care       Date:  2010-11-09       Impact factor: 9.097

10.  Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection.

Authors:  Kelvin K W To; Ivan F N Hung; Iris W S Li; Kar-Lung Lee; Chi-Kwan Koo; Wing-Wa Yan; Raymond Liu; Ka-Ying Ho; Kwok-Hong Chu; Chi-Leung Watt; Wei-Kwang Luk; Kang-Yiu Lai; Fu-Loi Chow; Thomas Mok; Tom Buckley; Jasper F W Chan; Samson S Y Wong; Bojian Zheng; Honglin Chen; Candy C Y Lau; Herman Tse; Vincent C C Cheng; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

View more
  6 in total

Review 1.  Protecting pediatric oncology patients from influenza.

Authors:  Leslie S Kersun; Anne F Reilly; Susan E Coffin; Kathleen E Sullivan
Journal:  Oncologist       Date:  2013-01-31

2.  Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.

Authors:  Sachiko Seo; Janet A Englund; Jack T Nguyen; Sasithon Pukrittayakamee; Niklas Lindegardh; Joel Tarning; Paul A Tambyah; Christian Renaud; Gregory T Went; Menno D de Jong; Michael J Boeckh
Journal:  Antivir Ther       Date:  2012-12-21

3.  The role of initial radiologic and clinical manifestations in predicting the prognosis for pneumonia caused by H1N1 influenza virus.

Authors:  Cemil Göya; Alpaslan Yavuz; Cihad Hamidi; Mehmet Güli Cetinçakmak; Memik Teke; Salih Hattapoğlu; Abdurrahim Duşak
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

4.  Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Grace E Lee; Brian T Fisher; Rui Xiao; Susan E Coffin; Kristen Feemster; Alix E Seif; Rochelle Bagatell; Yimei Li; Yuan-Shung V Huang; Richard Aplenc
Journal:  J Pediatric Infect Dis Soc       Date:  2014-07-22       Impact factor: 3.164

Review 5.  Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age.

Authors:  James E Fielding; Heath A Kelly; Geoffry N Mercer; Kathryn Glass
Journal:  Influenza Other Respir Viruses       Date:  2013-12-02       Impact factor: 4.380

6.  Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy.

Authors:  Eliana C A Benites; Dayane P Cabrini; Andrea C B Silva; Juliana C Silva; Daniel T Catalan; Eitan N Berezin; Maria R A Cardoso; Saulo D Passos
Journal:  J Pediatr (Rio J)       Date:  2014-04-02       Impact factor: 2.197

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.